Replies to post #153544 on Biotech Values

[oc631]

Arms 14 and 15 include GS-9669, a non-nuke!

It's amazing how companies with unlimited cash to spend on R&D can expand these studies away from their original design. This gives a new meaning to open-label. It's 22 Arms and counting.

Here's the original title of this study

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

So now we have GS-5885 and GS-9669. GILD is also testing GT1 nulls, GT1 naives, GT1 Hemophiliacs, and GT-1 prior null responders with cirrhosis. Also GT2/GT3 experienced patients and arms without riba.


I'm interested in how that non-nuke would work combined with sofosbuvir in GT2/GT3. Maybe that will be Arm-23?